UBE2V1 Antibody

UBE2V1

CIR1 antibody; CROC-1 antibody; CROC1 antibody; CROC1A antibody; TRAF6-regulated IKK activator 1 beta Uev1A antibody; UB2V1_HUMAN antibody; UBE2V 1 antibody; UBE2V antibody; UBE2V1 antibody; Ubiquitin conjugating enzyme E2 variant 1 antibody; Ubiquitin-conjugating enzyme E2 variant 1 antibody; UEV-1 antibody; UEV1 antibody

Recombinant Human Ubiquitin-conjugating enzyme E2 variant 1 protein (2-147AA)

Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes.

>95%, Protein G purified

Signal Transduction

Recombinant Human Ubiquitin-conjugating enzyme E2 variant 1 protein (2-147AA)